Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies
- 18 May 2001
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (6) , 445-447
- https://doi.org/10.1002/pd.94
Abstract
In a group of 149 women who had undergone routine first trimester screening using fetal nuchal translucency thickness (NT) and maternal serum free β-hCG and pregnancy associated plasma protein-A (PAPP-A) in two consecutive pregnancies the within person between pregnancy biological variability of these markers has been assessed. For fetal NT there was no correlation between NT MoM in the first and second pregnancy (r=0.0800). For maternal serum free β-hCG MoM a significant correlation was observed (r=0.4174) as was also found for PAPP-A MoM (r=0.3270). The implications for such between pregnancy marker association is that women who have an increased risk of Down syndrome in their first pregnancy are 1.5–2 times more likely to repeat this event in their next pregnancy. This observation may be useful in counselling women in the first trimester screening of a subsequent pregnancy. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 13 references indexed in Scilit:
- Screening for triploidy by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Maternal serum free ?-hCG and PAPP-A in fetal sex chromosome defects in the first trimesterPrenatal Diagnosis, 2000
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- Maternal age‐ and gestation‐specific risk for trisomy 21Ultrasound in Obstetrics & Gynecology, 1999
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998
- Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performancePrenatal Diagnosis, 1998
- Letter. Correct estimation of parameters for ultrasound nuchal translucency screeningPrenatal Diagnosis, 1998
- BETWEEN-PREGNANCY BIOLOGICAL VARIABILITY OF MATERNAL SERUM ALPHA- FETOPROTEIN AND FREE BETA hCG: IMPLICATIONS FOR DOWN SYNDROME SCREENING IN SUBSEQUENT PREGNANCIESPrenatal Diagnosis, 1997
- Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancyPrenatal Diagnosis, 1994